We are pleased to announce the appointment of a new advisor as of December 6, 2022.
We look forward to your continued support of the Industrial Hemp Association.
Japan Industrial Hemp Association Secretariat
・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
Counselor, Japan Hemp Association
Naoyuki Kamaya
<Brief Personal History>
He graduated from the University of Tokyo Faculty of Medicine in 1973, and has worked as a clinician and researcher in collagen disease, rheumatoid arthritis, gout, genetic and metabolic diseases, etc. at the University of Tokyo Hospital, Hitachi, Ltd.
From April 1979 to March 1982, he worked as a researcher at the Scripps Research Institute in California, USA, where he published papers that led to the development of the anti-leukemia drug cladribine, discovered the world’s first cancer suppressor gene MTAP, and developed personalized cancer treatment methods targeting MTAP deficiency.
From 1998 to 2008, he served as Director of the Center for Collagen Diseases, Rheumatology and Gout Center, Tokyo Women’s Medical University, where he led the cohort IORRA study of rheumatoid arthritis, clinical research on genomic pharmacology, and clinical development of febuxostat, a new treatment for hyperuricemia and gout.
He also has extensive overseas experience, including serving as a visiting professor of internal medicine at the University of Michigan in the United States from April 1989 to March 1990.
From April 2010 to December 2011, he served as Director of the RIKEN Center for Genomic Medicine, where he analyzed GWAS for various diseases.
He has published more than 600 papers.
Currently Director of the Institute for Medical Artificial Intelligence and President of the Gout Foundation
・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
